Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Foghorn Therapeutics (NAS:FHTX) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Foghorn Therapeutics 3-Year Book Growth Rate Related Terms
FHTX vs NWBO, FATE, IMRX: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Foghorn Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's 3-Year Book Growth Rate falls into.
Foghorn Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 0.00% mean?
Foghorn Therapeutics (FHTX) has a 3-Year Book Growth Rate of 0.00% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Foghorn Therapeutics and its competitors. According to the industry distribution chart, Foghorn Therapeutics ranks #999999 out of 1131 companies in the Biotechnology industry.
Is Foghorn Therapeutics' 3-Year Book Growth Rate too high?
Foghorn Therapeutics' current 3-Year Book Growth Rate is 0.00%. Based on the distribution chart, Foghorn Therapeutics ranks #999999 out of 1131 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Foghorn Therapeutics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' 3-Year Book Growth Rate compare to NWBO and FATE?
According to the Biotechnology industry distribution chart, Foghorn Therapeutics ranks #999999 out of 1131 companies for 3-Year Book Growth Rate. This places Foghorn Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Foghorn Therapeutics and its competitors. Foghorn Therapeutics's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.68 — trading 25.5% above its estimated fair value. The current 3-Year Book Growth Rate is 0.00%. Foghorn Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current 3-Year Book Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foghorn Therapeutics (FHTX) Overvalued in 2026?
Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be overvalued.
The current stock price of $6.68 is trading 25.5% above its estimated GF Value™ of $5.32.
GuruFocus considers Foghorn Therapeutics to be Modestly Overvalued.
Key valuation signals for FHTX:
3-Year Book Growth Rate: 0.00%
GF Value™: $5.32 vs. price of $6.68 (25.5% above fair value)
No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
67GF Score
Get the complete analysis for FHTX
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FHTX has been successfully added to your 
